- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Byfavo® | CNS-7056 | CNS7056
remimazolam is an approved drug (FDA (2020), EMA (2021))
Compound class: Synthetic organic
Comment: Remimazolam is a benzodiazepine type compound, that was developed as an ultra-short-acting sedative/anesthetic [3-4]. This compound combines the actions of the opioid analgesic remifentanil with that of the currently used sedative midazolam (GABAA receptor modulator). Remimazolam is proposed as a safer alternative to the current standard of care.
1. Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, Wilhelm-Ogunbiyi K. (2015)
A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy.
Anesth Analg, 120 (4): 771-80. [PMID:25502841]
2. Goudra BG, Singh PM. (2014)
Remimazolam: The future of its sedative potential.
Saudi J Anaesth, 8 (3): 388-91. [PMID:25191193]
3. Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL et al.. (2007)
CNS 7056: a novel ultra-short-acting Benzodiazepine.
Anesthesiology, 107 (1): 60-6. [PMID:17585216]
4. Rogers WK, McDowell TS. (2010)
Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.
IDrugs, 13 (12): 929-37. [PMID:21154153]